The panel recommends germline testing in PC patients with metastatic disease (1.3.1), ductal or intraductal histology (1.3.2), or positive FH (1.3.3), because significantly increased rates of germline mutations have been reported in these populations. The gene discussed is FH; the disease is metastatic neoplasm.